



PATENT Attorney Docket No.: 057309-5004-US02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re Application of: Robert BARGATZE et al.        | )                        |
|---|--------------------------|
| Application No. <b>10/780,650</b>                   | ) Art Unit: <b>1653</b>  |
| Filed: February 19, 2004                            | ) Examiner: Not Assigned |
| For: IDENTIFICATION OF PATHOGEN-LIGAND INTERACTIONS | )<br>)<br>)              |

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

Copies of the listed documents are enclosed. These documents were cited in an opposition request in the European application that corresponds to the parent of the present application. Applicants respectfully request that the Examiner consider the listed documents and indicate that the documents have been considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies the document as "prior art" against any claims in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**EXCEPT** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or to credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Dated: **February 1, 2005**Morgan, Lewis & Bockius LLP
Customer No. **09629**1111 Pennsylvania Avenue, NW

Washington, D.C. 20004 Telephone: (202) 739-3000

Facsimile: (202) 739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP

Bonnie Weiss McLeod Registration No. 43,255

## Attorney Docket No. Application No. 10/780,650 057309-5004-US02 **INFORMATION DISCLOSURE CITATION** (Use several sheets if necessary) Applicants: Robert BARGATZE et al. PAGE 1 of 1 PTO Form 1449 Filing Date: February 19, 2004 Group Art Unit: 1653 **U.S. PATENT DOCUMENTS** Class Sub-Class Filing Date Date Initial Document No. Name 12/29/1992 Hook et al. 69.1 05/09/1990 5,175,096 435 12/05/1991 02/23/1993 514 2 2. 5,189,015 Hook et al. 06/14/1994 69.1 01/22/1993 3. 5,320,951 Hook et al. 435 252.33 09/23/1993 05/16/1995 435 4. 5,416,021 Hook et al. 5,440,014 04/28/1994 5. 08/08/1995 Hook et al. 530 326 FOREIGN PATENT DOCUMENTS Sub-Class Translation Country Class Document No. Date OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Beachy (1981) J Infect Dis 143(5), 325-345 Bleiweis et al. (1992) Adv Exp Med Biol 327, 229-241 Brassart et al. (1991) Infection and Immunity 59(5), 1605-1613 8. 9. Burgess and McDonald (1992) Infection and Immunity 60(10), 4254-4259 Dean-Nystrom and Samuel (1994) Infection and Immunity 62(11), 4789-4794 Finlay and Falkow (1989) Microbial Reviews 53(2), 210-230 Hoepelman and Tuomanen (1992) Infection and Immunity 60(5), 1729-1733 12. 13. Jacobs et al. (1987) J Bacteriol 169(2), 735-741 Johnson (1991) Clinical Microbiology Reviews 4(1), 80-128 14. Kavoon et al. (1994) Ukr Biokhim Zh 66(2), 90-93 (Pubmed abstract only) 15. Mamo et al. (1994) Immunol Med Microbiol 10(1), 47-52 McGarey et al. (1994) Infection and Immunity 62(10), 4594-4601 17. 18. Payne et al. (1993) Infection and Immunity 61(9), 3673-3677 Petri and Ravdin (1991) Infection and Immunity 59(1), 97-101 19. 20. Prasad et al. (1993) Infection and Immunity 61(7), 2780-2785 Raja et al. (1990) Infection and Immunity 58(8), 2593-2598 21. 22. Ravdin (1989) J Infect Dis 159(3), 420-429 23. Raydin et al. (1986) Infection and Immunity 53(1), 1-5 Rozdzinske et al. (1993) J Exp Med 178, 917-924 24. Rozdzinski et al. (March 1995) J Clin Invest 95, 1078-1085 25. Saukkonen et al. (1992) PNAS 89, 118-122 26. Soong et al. (March 1995) J Infect Dis 171(3), 645-651 27. 28. Tham et al. (1994) J Bacteriol 176(3), 781-788 Wu et al (December 1995) Infection and Immunity 63(12), 4933-4938

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Examiner